Seeking Alpha

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX),, a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of ...
Benzinga.com

Armed With Donation From Trial Participant's Family, Cognition (Nasdaq: CGTX) Initiates Expanded Access Program For Experimental DLB Drug

Cognition Therapeutics Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including Dementia with Lewy Bodies (DLB), just received assistance in those ...
Hosted on MSN

Cognition reaches full enrollment in expanded access program for CT1812

Cognition Therapeutics (CGTX) announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg of oral zervimesine ...
Nasdaq

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
Seeking Alpha

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX),, a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded ...
Nasdaq

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...